CelLBxHealth plc
CLBX · AIM · Health Care · mcap £9.3m · 0.9p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 11 Aug 26 | Parsortix CTCs used for Brain Cancer detection
· Independent peer-reviewed study supports Parsortix® use in GBM |
+1.9% | |
| 03 Aug 26 | Parsortix CTCs used for ADC target assessment
· Parsortix® used to detect ADC-relevant targets on CTCs from breast and ovarian cancer patients |
+3.9% | |
| 16 Jul 26 | Issue of Share Options
Guildford, UK and Plymouth Meeting, U.S. - 16 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development |
−7.4% | |
| 15 Jul 26 | Results | Q2 and First Half Year Results ended 30 June 2026
Q2 and First Half Year Results ended 30 June 2026 |
−3.6% |
| 14 Jul 26 | Routine | Result of AGM | |
| 14 Jul 26 | AGM Statement
Guildford, UK and Plymouth Meeting, U.S. - 14 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development |
+1.8% | |
| 06 Jul 26 | Board change | Directorate Change
Guildford, UK and Plymouth Meeting, U.S. - 6 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development a |
+6.7% |
| 22 Jun 26 | Results | Final Results
Preliminary Results for the year ended 31 December 2025 |
−20.0% |
| 16 Jun 26 | Routine | Notice of Results | |
| 29 May 26 | MSA with Global Pharmaceutical Company
Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development a |
+24.6% | |
| 18 May 26 | Collaboration with AdventHealth for two studies
Collaboration with AdventHealth for two studies monitoring CTCs to improve cancer care |
−2.3% | |
| 11 May 26 | Trading update | Q1 trading update and outlook for 2026
Guildford, UK and Plymouth Meeting, U.S. - 11 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development an |
+22.0% |
| 30 Apr 26 | Trading update | Confirmation of Q1 trading update
Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development |
−2.7% |
| 20 Apr 26 | Research Collaboration with The Royal Marsden
Research Collaboration with The Royal Marsden NHS Foundation Trust |
+8.3% | |
| 16 Apr 26 | Board changes - Replacement
The following amendment has been made to the 'Board changes' announcement released on 12 January 2026 at 7:00 a.m. under RNS No 4265O. |
+0.0% | |
| 13 Feb 26 | Aligning Regulatory Approach with Commercial Needs
CelLBxHealth strengthens cost discipline by aligning FDA regulatory approach with current commercial needs |
+0.0% | |
| 16 Jan 26 | Results | Preliminary Fourth Quarter 2025 Financial Results
Guildford, UK and Plymouth Meeting, US - 16 January 2026 - CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical o |
−7.5% |
| 12 Jan 26 | Board change | Directorate Change
Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleas |
+0.0% |
| 23 Dec 25 | Holding | Holding(s) in Company | |
| 19 Dec 25 | Director dealing | PDMR Dealing and ESOT Share Purchase | |
| 15 Dec 25 | Results of General Meeting and Board Changes
Results of General Meeting and Proposed Board Changes |
−8.3% | |
| 02 Dec 25 | Fundraise | Additional Subscription
CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence is pleased to announce that further to the closing of the Retail Offer yesterday, Conifer Management, LLC, on behalf of the Acacia fund |
−2.2% |
| 01 Dec 25 | Fundraise | Result of Retail Offer
The Board of CELLBXHEALTH plc (the "Company") (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, is pleased to announce that the Retail Offer launched on 25 November 2025 has now closed, raising gross p |
−2.1% |
| 25 Nov 25 | Fundraise | Update to Admission of Fundraising Shares
CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence announces, following the conclusion of the oversubscribed Placing, the following update with regards Admission of the Fundraising Share |
−31.2% |
| 25 Nov 25 | Fundraise | Launch of Retail Offer
The Board of CelLBxHealth plc (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") in the capital of the Company (the "Retail Offer Shares") |
−31.2% |
| 25 Nov 25 | Fundraise | Result of Oversubscribed Placing and Subscription
596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). |
−31.2% |
| 24 Nov 25 | Fundraise | Proposed Placing and Subscription
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION INCLUDED IN APPENDIX I. |
−5.9% |
| 18 Nov 25 | QIAGEN Collaboration and Co-Marketing Agreement
Collaboration and co-marketing agreement with QIAGEN to advance CTC-based research with its pharmaceutical partners |
−5.6% | |
| 05 Nov 25 | Further Update on Funding
CELLBXHEALTH plc (AIM:CLBX), a global leader in circulating tumour cell (CTC) intelligence, announces, further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026. |
+4.8% | |
| 05 Nov 25 | CelLBxHealth Presents Proof-of-Concept Study
CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conference |
+4.8% | |
| 04 Nov 25 | Expert Consensus on CTCs; Update on Funding
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology |
−17.6% | |
| 29 Oct 25 | Routine | Change Of Name | |
| 16 Oct 25 | Board change | Appointments: Interim CEO and senior board advisor
APPOINTMENT OF INTERIM CEO AND SENIOR BOARD ADVISOR |
−7.9% |
| 08 Oct 25 | Strategy Update
Appointment of Executive Chairman, proposed change of name and strategy update |
−30.9% |
Company filings. Not investment advice.